Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting

Deitelzweig, 2013, Care transitions in anticoagulation management for patients with atrial fibrillation: an emphasis on safety, Ochsner J, 13, 419 Fang, 2006, Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study, J Am Geriatr Soc, 54, 1231, 10.1111/j.1532-5415.2006.00828.x Han, 2013, Anticoagulation management of patients with long-term warfarin therapy after valve replacement during the perioperative period of pacemaker implantation, Int J Clin Exp Med, 6, 594 Kamali, 2010, Pharmacogenetics of warfarin, Ann Rev Med, 61, 63, 10.1146/annurev.med.070808.170037 Moyer, 2009, Warfarin sensitivity genotyping: a review of the literature and summary of patient experience, Mayo Clin Proc, 84, 1079, 10.4065/mcp.2009.0278 Roth, 2014, Genetic risk factors for major bleeding in patients treated with warfarin in a community setting, Clin Pharmacol Ther, 95, 636, 10.1038/clpt.2014.26 Limdi, 2009, Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy, Blood Cells Mol Dis, 43, 119, 10.1016/j.bcmd.2009.01.019 Meckley, 2008, An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients, Thromb Haemost, 100, 229, 10.1160/TH07-09-0552 Mercaldi, 2011, Cost efficiency of anticoagulation with warfarin to prevent stroke in Medicare beneficiaries with nonvalvular atrial fibrillation, Stroke, 42, 112, 10.1161/STROKEAHA.110.592907 Allman-Farinelli, 2011, Obesity and venous thrombosis: a review, Semin Thromb Hemost, 37, 903, 10.1055/s-0031-1297369 Patel, 2011, Anticoagulating obese patients in the modern era, Br J Haematol, 155, 137, 10.1111/j.1365-2141.2011.08826.x Mueller, 2014, Warfarin dosing and body mass index, Ann Pharmacother, 48, 584, 10.1177/1060028013517541 Meyer zu Schwabedissen, 2006, Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes, Eur J Clin Pharmacol, 62, 713, 10.1007/s00228-006-0158-3 Tokumaru, 2016, Obesity increases risk of anticoagulation reversal failure with prothrombin complex concentrate in those with intracranial hemorrhage, Int J Neurosci, 126, 62, 10.3109/00207454.2014.993034 Caldwell, 2008, CYP4F2 genetic variant alters required warfarin dose, Blood, 111, 4106, 10.1182/blood-2007-11-122010 Higashi, 2002, Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy, JAMA, 287, 1690, 10.1001/jama.287.13.1690 Limdi, 2008, Warfarin pharmacogenetics, Pharmacotherapy, 28, 1084, 10.1592/phco.28.9.1084 Shendre, 2016, Race-specific influence of CYP4F2 on dose and risk of hemorrhage among warfarin users, Pharmacotherapy, 36, 263, 10.1002/phar.1717 Tomek, 2013, The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes, Cardiology, 125, 182, 10.1159/000350407 Dean, 2012, Warfarin therapy and the genotypes CYP2C9 and VKORC1 Roth, 2015, Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting, Pharmacoepidemiol Drug Saf, 24, 619, 10.1002/pds.3769 Arnason, 2006, Accuracy of coding for possible warfarin complications in hospital discharge abstracts, Thromb Res, 118, 253, 10.1016/j.thromres.2005.06.015 White, 1999, Major bleeding after hospitalization for deep-venous thrombosis, Am J Med, 107, 414, 10.1016/S0002-9343(99)00267-3 World Health Organization. Global database on body mass index. Available at: http://apps.who.int/bmi/index.jsp?introPage=intro_3.html. Accessed April 19, 2014. Hylek, 1998, Acetaminophen and other risk factors for excessive warfarin anticoagulation, JAMA, 279, 657, 10.1001/jama.279.9.657 Lindh, 2005, Several-fold increase in risk of overanticoagulation by CYP2C9 mutations, Clin Pharmacol Ther, 78, 540, 10.1016/j.clpt.2005.08.006 Simes, 1986, An improved Bonferroni procedure for multiple tests of significance, Biometrika, 73, 751, 10.1093/biomet/73.3.751 Ogunsua, 2015, Body mass index predicts major bleeding risks in patients, J Thromb Thrombolysis, 40, 494, 10.1007/s11239-015-1226-2